BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Liu S, Wu F, Li X, Zhao C, Jia Y, Jia K, Han R, Qiao M, Li W, Yu J, Zhou F, Xiong A, Chen B, Fan J, Ren S, Zhou C. Patients With Short PFS to EGFR-TKIs Predicted Better Response to Subsequent Anti-PD-1/PD-L1 Based Immunotherapy in EGFR Common Mutation NSCLC. Front Oncol 2021;11:639947. [PMID: 33777802 DOI: 10.3389/fonc.2021.639947] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 11.0] [Reference Citation Analysis]
Number Citing Articles
1 Zhou S, Ren F, Meng X. Efficacy of immune checkpoint inhibitor therapy in EGFR mutation-positive patients with NSCLC and brain metastases who have failed EGFR-TKI therapy. Front Immunol 2022;13:955944. [DOI: 10.3389/fimmu.2022.955944] [Reference Citation Analysis]
2 Morimoto K, Sawada R, Yamada T, Azuma K, Ito K, Goto Y, Kimura H, Harada T, Shiotsu S, Tamiya N, Chihara Y, Takeda T, Hiranuma O, Hasegawa I, Morimoto Y, Iwasaku M, Tokuda S, Takayama K. A Real-World Analysis of Immune Checkpoint Inhibitor-Based Therapy After Osimertinib Treatment in Patients With EGFR-Mutant NSCLC. JTO Clinical and Research Reports 2022;3:100388. [DOI: 10.1016/j.jtocrr.2022.100388] [Reference Citation Analysis]
3 Liu QX, Wei JG, Chen YY, Wang JF. Efficacy and safety of pembrolizumab monotherapy in EGFR-mutant squamous cell lung cancer with PD-L1 over-expression: A case report. Medicine (Baltimore) 2022;101:e30099. [PMID: 35984168 DOI: 10.1097/MD.0000000000030099] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Ding Y, Dong H, Li Y, Liu L, Cai Y, Wang Y, Tian S, Dai C. De Novo mutation in Epidermal growth factor receptor (EGFR)-D761Y responding to third generation tyrosine kinase inhibitor Osimertinib: A case report. Medicine (Baltimore) 2022;101:e29332. [PMID: 35866776 DOI: 10.1097/MD.0000000000029332] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
5 Shi C, Wang Y, Xue J, Zhou X. Immunotherapy for EGFR-mutant advanced non-small-cell lung cancer: Current status, possible mechanisms and application prospects. Front Immunol 2022;13:940288. [DOI: 10.3389/fimmu.2022.940288] [Reference Citation Analysis]
6 Xu L, Zou C, Zhang S, Chu TSM, Zhang Y, Chen W, Zhao C, Yang L, Xu Z, Dong S, Yu H, Li B, Guan X, Hou Y, Kong FM. Reshaping the systemic tumor immune environment (STIE) and tumor immune microenvironment (TIME) to enhance immunotherapy efficacy in solid tumors. J Hematol Oncol 2022;15:87. [PMID: 35799264 DOI: 10.1186/s13045-022-01307-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
7 Bai M, Wang W, Gao X, Wu L, Jin P, Wu H, Yu J, Meng X. Efficacy of Immune Checkpoint Inhibitors in Patients With EGFR Mutated NSCLC and Potential Risk Factors Associated With Prognosis: A Single Institution Experience. Front Immunol 2022;13:832419. [DOI: 10.3389/fimmu.2022.832419] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
8 Zhou F, Guo H, Zhou X, Xie H, Tian T, Zhao W, Gao G, Xiong A, Wang L, Li W, Chen X, Zhang Y, Fan J, Wu F, Zhang Y, Zhou C. Immune checkpoint inhibitors plus chemotherapy in patients with locally advanced or metastatic pulmonary sarcomatoid carcinoma: a multicentric real-world study. Ther Adv Med Oncol 2022;14:175883592211367. [DOI: 10.1177/17588359221136759] [Reference Citation Analysis]
9 Wiest N, Majeed U, Seegobin K, Zhao Y, Lou Y, Manochakian R. Role of Immune Checkpoint Inhibitor Therapy in Advanced EGFR-Mutant Non-Small Cell Lung Cancer. Front Oncol 2021;11:751209. [PMID: 34868953 DOI: 10.3389/fonc.2021.751209] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
10 Shen CI, Chao HS, Shiao TH, Chiang CL, Huang HC, Luo YH, Chiu CH, Chen YM. Comparison of the outcome between immunotherapy alone or in combination with chemotherapy in EGFR-mutant non-small cell lung cancer. Sci Rep 2021;11:16122. [PMID: 34373555 DOI: 10.1038/s41598-021-95628-w] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
11 Qiao M, Jiang T, Liu X, Mao S, Zhou F, Li X, Zhao C, Chen X, Su C, Ren S, Zhou C. Immune Checkpoint Inhibitors in EGFR-Mutated NSCLC: Dusk or Dawn? J Thorac Oncol 2021;16:1267-88. [PMID: 33915248 DOI: 10.1016/j.jtho.2021.04.003] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 31.0] [Reference Citation Analysis]